The 36-month beta value for ALDX is at 0.91. Analysts have varying views on the stock, with 6 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ALDX is 57.98M, and currently, shorts hold a 6.89% of that float. The average trading volume for ALDX on March 31, 2025 was 523.57K shares.
ALDX) stock’s latest price update
Aldeyra Therapeutics Inc (NASDAQ: ALDX) has experienced a rise in its stock price by 6.55 compared to its previous closing price of 6.26. However, the company has seen a gain of 1.37% in its stock price over the last five trading days. seekingalpha.com reported 2025-03-05 that Aldeyra’s reproxalap faced an FDA setback but showed positive trial results, leading to a resubmitted NDA with a PDUFA date of April 2025. Despite a controversial deal with AbbVie, Aldeyra remains financially solid, with $100M in cash and potential milestone payments. The DED market is strong, and reproxalap’s data surpasses competitors, indicating significant undervaluation of Aldeyra’s stock.
ALDX’s Market Performance
Aldeyra Therapeutics Inc (ALDX) has experienced a 1.37% rise in stock performance for the past week, with a 5.21% rise in the past month, and a 40.27% rise in the past quarter. The volatility ratio for the week is 7.03%, and the volatility levels for the past 30 days are at 9.35% for ALDX. The simple moving average for the past 20 days is 2.12% for ALDX’s stock, with a 29.78% simple moving average for the past 200 days.
Analysts’ Opinion of ALDX
Many brokerage firms have already submitted their reports for ALDX stocks, with Oppenheimer repeating the rating for ALDX by listing it as a “Outperform.” The predicted price for ALDX in the upcoming period, according to Oppenheimer is $10 based on the research report published on April 03, 2024 of the previous year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see ALDX reach a price target of $10. The rating they have provided for ALDX stocks is “Buy” according to the report published on April 02nd, 2024.
H.C. Wainwright gave a rating of “Buy” to ALDX, setting the target price at $15 in the report published on April 27th of the previous year.
ALDX Trading at 9.95% from the 50-Day Moving Average
After a stumble in the market that brought ALDX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -7.36% of loss for the given period.
Volatility was left at 9.35%, however, over the last 30 days, the volatility rate increased by 7.03%, as shares surge +30.53% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +32.74% upper at present.
During the last 5 trading sessions, ALDX rose by +1.37%, which changed the moving average for the period of 200-days by +72.35% in comparison to the 20-day moving average, which settled at $6.53. In addition, Aldeyra Therapeutics Inc saw 33.67% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ALDX starting from Machatha Stephen, who sale 16,041 shares at the price of $4.74 back on Aug 12 ’24. After this action, Machatha Stephen now owns 236,771 shares of Aldeyra Therapeutics Inc, valued at $75,975 using the latest closing price.
Greenberg Bruce, the of Aldeyra Therapeutics Inc, sale 10,834 shares at $4.74 during a trade that took place back on Aug 12 ’24, which means that Greenberg Bruce is holding 126,382 shares at $51,313 based on the most recent closing price.
Stock Fundamentals for ALDX
Current profitability levels for the company are sitting at:
- -245.85 for the present operating margin
- 0.5 for the gross margin
The net margin for Aldeyra Therapeutics Inc stands at -228.41. The total capital return value is set at -0.7. Equity return is now at value -58.54, with -44.16 for asset returns.
Based on Aldeyra Therapeutics Inc (ALDX), the company’s capital structure generated 0.18 points at debt to capital in total, while cash flow to debt ratio is standing at -2.82. The debt to equity ratio resting at 0.22. The interest coverage ratio of the stock is -31.21.
Currently, EBITDA for the company is -60.12 trillion with net debt to EBITDA at 0.73. When we switch over and look at the enterprise to sales, we see a ratio of 1468.28. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.48.
Conclusion
In conclusion, Aldeyra Therapeutics Inc (ALDX) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
